Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Adenocarcinoma of Esophagogastric Junction.”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07727993
What this trial is testing

Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction AdenocarcinomaPropranololSOX Chemotherapy+1 more
Ting Liu 49
Testing effectiveness (Phase 2)Study completedNCT04276493
What this trial is testing

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Cancer
BeiGene 71
Testing effectiveness (Phase 2)Looking for participantsNCT04018872
What this trial is testing

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Who this might be right for
Esophagus AdenocarcinomaEsophagus Squamous Cell CarcinomaGastroesophageal Junction Adenocarcinoma
Dallas VA Medical Center 78
Testing effectiveness (Phase 2)Looking for participantsNCT07069712
What this trial is testing

Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Who this might be right for
Gastroesophageal Adenocarcinoma
AstraZeneca 100
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Not applicableStudy completedNCT01582906
What this trial is testing

A Survivorship Care Plan for Gynaecological Cancer Patients

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionCervical CancerEndometrial Cancer+7 more
Royal Marsden NHS Foundation Trust 150
Testing effectiveness (Phase 2)Ended earlyNCT04034251
What this trial is testing

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Who this might be right for
Gastric AdenocarcinomaGastric CancerEsophagogastric Junction+1 more
National Cancer Institute (NCI) 12
Not applicableStudy completedNCT03528629
What this trial is testing

IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric CancerGastro-esophageal Junction (GEJ) Cancer
Astellas Pharma Inc 18
Early research (Phase 1)Study completedNCT01962532
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Who this might be right for
NeoplasmsLymphomaAdenocarcinoma+1 more
Janssen Research & Development, LLC 19
Large-scale testing (Phase 3)Study completedNCT00680901
What this trial is testing

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Who this might be right for
Neoplasms, Gastrointestinal Tract
Novartis Pharmaceuticals 545
Not applicableNot Yet RecruitingNCT07800819
What this trial is testing

Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction

Who this might be right for
Gastric AdenocarcinomaAdenocarcinoma of the Esophagogastric Junction
The First Affiliated Hospital with Nanjing Medical University 250
Large-scale testing (Phase 3)Study completedNCT01107639
What this trial is testing

Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionEsophageal Cancer
Swiss Cancer Institute 297
Testing effectiveness (Phase 2)Active Not RecruitingNCT07143604
What this trial is testing

Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
AstraZeneca 33
Early research (Phase 1)Study completedNCT00004879
What this trial is testing

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Who this might be right for
Colorectal CancerEsophageal CancerKidney Cancer+3 more
Jonsson Comprehensive Cancer Center
Not applicableUnknownNCT04443478
What this trial is testing

Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer

Who this might be right for
Gastric Cancer
Peking University 1,036
Large-scale testing (Phase 3)Study completedNCT00678535
What this trial is testing

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer

Who this might be right for
Gastric Cancer
Merck KGaA, Darmstadt, Germany 904
Testing effectiveness (Phase 2)UnknownNCT05948449
What this trial is testing

To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Gastric Cancer
Sichuan University 37
Testing effectiveness (Phase 2)Study completedNCT00397904
What this trial is testing

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)UnknownNCT06396585
What this trial is testing

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Who this might be right for
Immunotherapy Gastroesophageal Junction
Fujian Cancer Hospital 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT02962063
What this trial is testing

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Who this might be right for
Esophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center 64
Next Page